CVRx, Inc. downgraded by JP Morgan with a new price target
$CVRX
Medical/Dental Instruments
Health Care
JP Morgan downgraded CVRx, Inc. from Overweight to Neutral and set a new price target of $13.00 from $36.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $14.00 | Overweight | Cantor Fitzgerald |
| 7/11/2024 | $18.00 → $12.00 | Buy | Lake Street |
| 5/1/2024 | $30.00 → $23.00 | Buy | Craig Hallum |
| 5/1/2024 | Outperform → Mkt Perform | William Blair | |
| 5/1/2024 | $36.00 → $13.00 | Overweight → Neutral | JP Morgan |
| 1/31/2023 | $20.00 | Buy | Lake Street |
| 7/18/2022 | $15.00 | Buy | Craig Hallum |
| 7/26/2021 | Outperform | William Blair |
SC 13D/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
SC 13G/A - CVRx, Inc. (0001235912) (Subject)
144 - CVRx, Inc. (0001235912) (Subject)
144 - CVRx, Inc. (0001235912) (Subject)
8-K - CVRx, Inc. (0001235912) (Filer)
Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00
Lake Street reiterated coverage of CVRx, Inc. with a rating of Buy and set a new price target of $12.00 from $18.00 previously
Craig Hallum resumed coverage of CVRx, Inc. with a rating of Buy and set a new price target of $23.00 from $30.00 previously
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, Inc. CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of h
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. The APC payment of approximately $45,000 will continue in 2025, as published in the 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. This follows the recent announcement that the American Medical Association CPT® Editorial Panel approved the application to transition Barostim from Category III to Category I CPT codes, expected to be implemented on January 1, 2026. Additi
MINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2024. Recent Highlights Total revenue for the third quarter 2024 was $13.4 million, an increase of 27% over the prior year quarterU.S. Heart Failure (HF) revenue for the third quarter of 2024 was $12.2 million, an increase of 30% over the prior year quarterActive implanting centers in the U.S. were 208, an increase of 31% over the prior year quarterFinal I
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
4 - CVRx, Inc. (0001235912) (Issuer)
Craig-Hallum analyst Alexander Nowak maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $23 to $15.
CVRx (NASDAQ:CVRX) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 1 1 0 0 Analysts have recently evaluated CVRx and provided 12-month price targets. The average target is $15.83, accompanied by a high estimate of $23.00 and a low estimate of $12.00. Experiencing a 48.39% decline, the current averag
Lake Street analyst Frank Takkinen maintains CVRx (NASDAQ:CVRX) with a Buy and lowers the price target from $18 to $12.
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and
Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe
MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b
MINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2024. Recent Highlights Total revenue for the third quarter 2024 was $13.4 million, an increase of 27% over the prior year quarterU.S. Heart Failure (HF) revenue for the third quarter of 2024 was $12.2 million, an increase of 30% over the prior year quarterActive implanting centers in the U.S. were 208, an increase of 31% over the prior year quarterFinal I
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to th
MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024. Recent Highlights Total revenue for the second quarter 2024 was $11.8 million, an increase of 24% over the prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2024 was $10.5 million, an increase of 27% over the prior year quarterActive implanting centers in the U.S. were 189, an increase of 35% over the second quarter of 2023